Clinical trials
Hemophilia A clinical trials
Below are recruiting hemophilia a clinical trials, each written for real people, not researchers. We’re tracking 92 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05611801RecruitingPhase 3
Marstacimab trial for children with hemophilia A or B
This Phase 3 study tests marstacimab, a new medicine, to help prevent or better control bleeding in children and teens with hemophilia A or hemophilia B. You may be eligible if your child’s past records show ongoing bleeding and treatment with factor replacement (or specific inhibitor-related patterns).
Salt Lake City, UtahAges 1–17 - NCT06349473RecruitingPhase 1
Study of SR604 in healthy people and those with bleeding disorders
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
Glendale, CaliforniaAges 18–60 - NCT06565481Recruiting
Testing movement and function in people with hemophilia
This study looks at how well certain tests measure movement and function in people with hemophilia. It may help improve how doctors track your condition.
ZurichAges 18 years+ - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT07414511Recruiting
Hemophilia A research study for pregnant families
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Seattle, WashingtonAges Any age - NCT03327779Recruiting
Bleeding disorders registry for blood-clotting conditions
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
Montreal, QuebecAges Any age - NCT04645199Recruiting
Long-term follow-up study for blood and bone marrow diseases
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
Tianjin, Tianjin MunicipalityAges Any age - NCT04647227RecruitingPhase 4
SEVENFACT® to reduce bleeding in hemophilia with inhibitors
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Phoenix, ArizonaAges 12–100 - NCT05145127RecruitingPhase 3
Marstacimab follow-up study for people with hemophilia
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
Iowa City, IowaAges 1–74 - NCT05568719RecruitingPhase 3
Testing gene therapy for hemophilia A or B
This Phase 3 trial is checking how safe and effective two gene therapies are for people with hemophilia A or hemophilia B. It only includes people who already received the study medicines through specific Pfizer studies, so it’s mainly for that existing participant group.
Rancho Cordova, CaliforniaAges 18 years+ - NCT05802836Recruiting
Tracking an antibody response in severe hemophilia A on emicizumab
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
Frankfurt am Main, HesseAges Any age - NCT06320626RecruitingPhase 4
Personalized emicizumab dosing for hemophilia A
This trial tests whether adjusting emicizumab (Hemlibra) doses based on your body's drug levels can safely maintain good bleed control in people with hemophilia A who have been on the drug for at least a year.
Nijmegen, GelderlandAges 1 year+ - NCT06820515Recruiting
Blood disorder patient registry for all ages
This study is a registry (a large database) that collects information from people who have or may have a blood disorder. It helps researchers learn more about these conditions and improve care.
Hickory, North CarolinaAges Any age - NCT02912143Recruiting
Hemophilia pediatric research registry database
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
Frankfurt am Main, HesseAges Up to 18 years - NCT07644832RecruitingPhase 1/Phase 2
New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
ChangshaAges 18–65 - NCT06003387RecruitingPhase 3
Gene therapy for hemophilia B with AAV5 antibodies
This trial tests a gene therapy called CSL222 for adults with hemophilia B who have antibodies against the AAV5 virus used to deliver the therapy. It aims to see if the treatment is safe and effective even when these antibodies are present.
San Diego, CaliforniaAges 18 years+ - NCT07787091RecruitingPhase 1/Phase 2
First study of ARD001 in healthy people and those with hemophilia A
This study tests a new medicine, ARD001, for the first time in humans. It aims to see if the drug is safe and how the body handles it, and it is also being studied in people with hemophilia A to find a safe dose for future trials.
SingaporeAges 21–45 - NCT07080905RecruitingPhase 3
Gene therapy for teens with severe hemophilia B
This trial tests a single dose of CSL222, a gene therapy, in adolescent boys with severe or moderately severe hemophilia B. The goal is to see if it can reduce or eliminate the need for regular factor IX infusions.
Orange, CaliforniaAges 11.5 years–17.2 years - NCT07416604RecruitingPhase 3
Study of NXT007 vs emicizumab for hemophilia A
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Orange, CaliforniaAges 12 years+ - NCT07416526RecruitingPhase 3
Testing NXT007 for hemophilia A without inhibitors
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Aurora, ColoradoAges 12 years+ - NCT05849740RecruitingPhase 4
CD38 antibody plus steroid for acquired hemophilia A
This trial studies whether a CD38-targeting antibody together with corticosteroids can improve outcomes in acquired hemophilia A. It is an “exploratory” Phase 4 study, meaning the goal is to learn more about safety and effectiveness in real-world patients.
TianjinAges 18 years+ - NCT05981274Recruiting
Bone health study of a long-acting factor VIII for hemophilia A
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Taipei, Neihu Dist.Ages Any age - NCT06550882Recruiting
Study of Obizur for adults with acquired hemophilia A in South Korea
This study is for adults in South Korea with acquired hemophilia A, a rare bleeding disorder. It tests a drug called Obizur to see how well it works for people who need it to control bleeding.
SeoulAges 18 years+ - NCT05888870RecruitingPhase 4
Testing a treatment for hemophilia A with inhibitor antibodies
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
TianjinAges 14–65
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hemophilia A trials by city
Studies with a site in or near these metro areas.
Hemophilia A trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hemophilia a?
- Yes. Clin2 currently lists 92 recruiting hemophilia a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophilia a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophilia a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.